



Together we are stronger! Transo-Pharm and HAPILA expand cooperation

What started off as a strategic alliance has emerged over the years to a trusting partnership, in which we have successfully combined the respective core competencies and strengths.

This is an essential reason for us not only to shape the present together - but also the future.

We, Transo-Pharm Handels-GmbH and HAPILA GmbH, have jointly decided to expand the production capacities at the HAPILA site in Gera - also in order to meet the increasing demand for the active ingredient Estriol Micronized (CEP no.: R1-CEP 2013-277-Rev 00). The planning for the Construction and installation work started in 2020. The new facility is expected to be completed in 2022.

Core competencies & strengths of HAPILA GmbH:

- Development of chemical API synthesis and GMP-compliant manufacturing of active pharmaceutical ingredients
- Regulatory documentation (ASMF, CEP etc.)

Core competencies & strengths of Transo-Pharm Handels-GmbH:

- International marketing, development and sales of active pharmaceutical ingredients
- Logistics (including GMP-compliant storage and GDP-compliant shipping)



HAPILA innovation and experience in the experience i

January 12, 2022 page 1